Multiple sclerosis patients clinical and anthropometric measurements relationship between demographic characteristics

Multiple sclerosis (MS) is an autoimmune, chronic, inflammatory, progressive, axonal and demyelinating neurological disease of the central nervous system (CNS). The relationship between Multiple Sclerosis and nutrition has continued to be investigated for the last 50 years. Body composition is associated with the progression of MS. Excess weight/obesity increases neuroinflammation and the risk of disease progression and recurrence. In this study, the values measured with the Tanita BC 418 device retrospectively, BMI value, metabolic rate, total and segmental values in the body, of 356 patients aged 18-65 years, who applied to the Neurology clinic between 15 October 2019 and 15 October 2022, were diagnosed with MS. fat and muscle ratio, biochemical blood findings and MRI findings were evaluated. As a result of the analysis, a significant relationship was found between some blood values and the total fat, muscle mass and percentages, FFM and TBV values of the patients, both in the negative and positive direction, at both low, moderate and large levels, p≤.050. A significant difference was found between the mean MS duration of the non-obese (BMI<25) (X̄=6.95, SD=5.30) and the mean MS duration of the obese (BMI=25+) (X̄=9.23, SD=6.39), t(263) )=3.09, p=.002. Those who are obese are more likely to have MS than those without. Again, according to the results of the analysis, a significant difference was found between the mean metabolic rate of the non-obese (BMI<25) (X̄=1406.65, SD=220.69) and the mean metabolic rate of the obese (BMI=25+) (X̄=1595.32, SD=280.16). t(354)=6.96, p<.001. People who are obese have a higher metabolic rate than those who are not obese. A significant difference was found between MS drug types in terms of total non-fat mass (FFM), F(5, 232)=2.83, p=.017. As a result of bonferroni post hoc analysis performed to determine which drug types there is a significant difference, there was a significant difference between Interferon beta-1 (X̄=45.77, SS=9.39) and teriflunomide (X̄=53.06, SS=12.15), Interferon beta- 1 users were found to have less non-fat mass and TBV than teriflunomide. MS is a major cause of disability in young adults and its incidence is increasing from year to year. MS disease significantly affects the quality of life of individuals, both physically and mentally. For this reason, it is necessary to investigate and know the factors that affect the progression of the disease and the quality of life of the patients.